One-on-One With U.S. AstraZeneca Coronavirus Vaccine Trial Participant

While AstraZeneca has been authorized for use across the EU, it is just releasing phase 3 U.S. trial results. The drug maker has been criticized for so called 'cherry picking' vaccine data after revealing it was 79% effective earlier this week. The pharma giant recalculated data from the disputed U.S. study and said it found its vaccine to be 76% effective at preventing symptomatic cases. We were joined by Amy Nichols who is a participant in the U.S. AstraZeneca coronavirus vaccine trial to learn more about what it was like to be involved in the trial.
We use cookies and similar technologies on this site to collect identifiers, such as IP address, and cookie and device IDs as described in our Privacy Policy.